RNA interference targeting the platelet-derived growth factor receptor β subunit ameliorates experimental hepatic fibrosis in rats by Chen, Si-Wen et al.
BASIC STUDIES
RNAinterferencetargetingtheplatelet-derivedgrowthfactor
receptorbsubunitamelioratesexperimentalhepatic¢brosisinrats
Si-Wen Chen
1, Xing-Rong Zhang
1, Chong-Ze Wang
2, Wei-Zhong Chen
1, Wei-Fen Xie
1 and
Yue-Xiang Chen
1
1 Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai, China
2 Department of Geriatrics, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
OnlineOpen: This article is available free online at www.blackwell-synergy.com
Keywords
cell proliferation – gene therapy – hepatic
ﬁbrosis – hepatic stellate cells – platelet-
derived growth factor receptor b subunit
(PDGFR-b) – RNA interference
Abbreviations
a-SMA, a-smooth muscle actin; ALT, alanine
aminotransferase; AST, aspartate
aminotransferase; BDL, bile duct ligation; DB,
direct bilirubin; DMN, dimethylnitrosamine;
ECM, extracellular matrix; ERK, extracellular-
signal-related kinase; HSCs, hepatic stellate
cells; MAPK, mitogen-activated protein
kinases; PDGF, platelet-derived growth factor;
PDGFR-b, PDGF receptor b subunit; RNAi,
RNA interference; siRNA, small interference
RNA; shRNA, short hairpin RNA; TB, total
bilirubin
Correspondence
Yue-Xiang Chen, Department of
Gastroenterology, Changzheng Hospital,
Second Military Medical University, Shanghai
200003, China
Tel: 186 21 6361 0109
Fax: 186 21 –6352 0020
e-mail: yuexchen1807@yahoo.com.cn
Received 2 March 2008
Accepted 4 March 2008
DOI:10.1111/j.1478-3231.2008.01759.x
Abstract
Background/Aims: Platelet-derived growth factor (PDGF) is the strongest stimu-
lator of the proliferation of hepatic stellate cells (HSCs). PDGF receptor b subunit
(PDGFR-b) is acquired on HSCs proliferation induced by PDGF. In this study, we
aim to investigate the effect of PDGFR-b small interference RNA (siRNA) on
experimental hepatic ﬁbrosis. Methods: We constructed a PDGFR-b siRNA
expression plasmid and investigated its effect on the activation of HSCs.
Bromodeoxyuridine incorporation was performed to investigate the effect of
PDGFR-b siRNA on HSCs proliferation. A hydrodynamics-based transfection
method was used to deliver PDGFR-b siRNA to rats with hepatic ﬁbrosis. The
distribution of transgenes in the liver was observed by immunoﬂuorescence.
The antiﬁbrogenic effect of PDGFR-b siRNA was investigated pathologically.
Results: Platelet-derived growth factor receptor-b subunit siRNA could signiﬁ-
cantly downregulate PDGFR-b expression, suppress HSCs activation, block the
mitogen-activated protein kinase signalling pathway and inhibit HSCs prolifera-
tion invitro. PDGFR-b siRNAexpression plasmid could be deliveredinto activated
HSCs by the hydrodynamics-based transfection method, and remarkably improve
the liver function of the rat model induced by dimethylnitrosamine and bile duct
ligation. Furthermore, the progression of ﬁbrosis in the liver was signiﬁcantly
suppressed by PDGFR-b siRNA in both animal models. Conclusions: Platelet-
derived growth factor receptor-b subunit siRNA may be presented as an effective
antiﬁbrogenic gene therapeutic method for hepatic ﬁbrosis.
Hepatic ﬁbrosis characterized by the excess produc-
tion and deposition of extracellular matrix (ECM)
components is the common ﬁnal pathway in most
chronic liver diseases. Although the exact mechanisms
of hepatic ﬁbrosis are not fully understood, it is known
that the activation of hepatic stellate cells (HSCs)
characterized by the morphological transition to myo-
ﬁbroblast-like cells is the key event of the pathogenesis
of hepatic ﬁbrosis (1, 2). The phenotype of activated
HSCs may be inﬂuenced by several growth factors and
cytokines, including the platelet-derived growth factor
(PDGF), which is the most potent mitogen for acti-
vated HSCs. In response to PDGF, activated HSCs
display enhanced mitogenicity and increased produc-
tion of ECM (3).
Reuse of this article is permitted in accordance with the
Creative Commons Deed, Attribution 2.5, which does not
permit commercial exploitation.
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chains: PDGF-A, -B, -C and - D. PDGF-A and -B are
secreted as homodimers or heterodimers and are
involved in autocrine and paracrine stimulation of
HSCs proliferation (4), while the latter two form only
homodimers (5–7). The PDGF receptor is a structu-
rally related tyrosine kinase that is a homodimer or a
heterodimer of a or b subunits. The PDGF receptor
(PDGFR)-a subunit is constitutively expressed in
quiescent HSCs, whereas PDGFR-b is acquired when,
during the activation of HSCs, PDGF-A binds to the
a subunit only, while PDGF-B is a ligand for both the
receptor subunits (4, 8). It is well known that PDGF-
BB is the strongest stimulator of HSCs proliferation.
The expression of PDGF and PDGFR-b was demon-
strated to correlate with necrotic inﬂammation and
ﬁbrosis in ﬁbrotic liver, clearly reﬂecting the essential
role of PDGF and PDGFR-b in the pathogenesis of
hepatic ﬁbrosis (9). Therefore, a number of studies
have focused on the treatment of hepatic ﬁbrosis by
targeting PDGF, PDGFR and molecules related to the
PDGF intracellular signalling transduction pathway,
and have achieved a favourable antiﬁbrogeniceffect. In
this study, we constructed a PDGFR-b short hairpin
RNA (shRNA) expression vector, which showed high
gene-silencing efﬁcacy and an antiproliferative effect
in vitro, and investigated its antiﬁbrogenic effect on
experimental hepatic ﬁbrosis induced by dimethyl-
nitrosamine (DMN) and bile duct ligation (BDL).
Materials and methods
Generation of plasmids
The 21-nucleotide small interference RNA (siRNA)
against rat PDGFR-b gene with a high gene-silencing
efﬁcacy (sense: GUGGACUCCGAUACUUACUtt; anti-
sense: AGUAAGUAUCGGAGUCCACtt) and its nega-
tive control RNA (sense: UUCUCCGAACGUGUCA
CGUtt; antisense: ACGUGACACGUUCGGAGAAtt)
were chemically synthesized by Shanghai Sangon
Biological Engineering Technology & Service Co. Ltd
(Shanghai, China). The shRNAs corresponding to
PDGFR-b siRNA and its negative control containing
the 9-nucleotide loop sequence (TTCAAGAGA)
ﬂanked by sense and antisense siRNA sequences were
synthesized by the polymerase chain reaction (PCR).
The PDGFR-b shRNA was inserted immediately into
the miR30-based shRNA expression system of the
pCMR30 vector (Genechem, Shanghai, China) to gen-
erate a pCMV–shRNA–red ﬂuorescent protein (RFP),
in which PDGFR-b shRNA was driven by the CMV
promoter and RFP was the reporter gene. To generate
pCMV–shRNA–LacZ, the fragment containing miR30-
based PDGFR-b shRNA was PCR-cloned into the
HindIII site of the pMIR-REPORT b-gal reporter con-
trol vector (Ambion, Austin, TX, USA), which supplies
the b-gal reporter gene. As a negative control, we
generated pCMV–NC–LacZ with miR30-based
PDGFR-b shRNA in pCMV–shRNA–LacZ replaced by
negative control RNA. All the generated plasmids were
identiﬁedbyPCRandsequencing.Detailedvectormaps
and sequence information are available on request.
Cell culture and transfection
The rat HSC-T6 cell line was a generous gift from
Dr Scott Friedman of the Mount Sinai School of
Medicine in New York, USA (10). The cells were cultured
in Dulbecco’s modiﬁed medium containing 10% fetal
bovine serum (Gibco, Grand Island, NY, USA). Transient
transfection using Lipofectamine 2000 (Invitrogen, Carls-
bad, CA, USA) wascarried out in six-well plates with 6mg
plasmids/35mm culture plate when cells reach 60–70%
conﬂuence. The medium for culture was changed with
fresh medium at 6h after transfection. The serum con-
tent was reduced to 0.25% fetal bovine serum 24h later
a n dt h ec e l l sw e r es t i m u l a t e dw i t h2 0 n g / m lP D G F - B B
(Sigma, Saint Louis, MO, USA) for another 24h.
Reverse transcription-polymerase chain reaction assay
Total RNAwas isolated with Trizol reagent (Invitrogen)
from the cells that were transfected with plasmids and/
or stimulated by PDGF-BB. Reverse transcription-poly-
merase chain reaction (RT-PCR) was performed using
the RT-PCR kit (Takara, Otsu, Japan). Primers against
PDGFR-b mRNA (sense: CACCATTTCGAGCACCTT
TGT; antisense: AGGGCACTCCGAAGAGGTAA),
b-actin mRNA (sense: CTTGACCCTGAAGTATCCC;
antisense: TATTGAAGTGGTGGTGTCG) and a-smooth
muscle actin (a-SMA) mRNA (sense: CAGGGAGTGAT
GGTTGGA; antisense: AGACGGAGTACGGTAGTA)
were designed according to Pubmed GenBank and
synthesized by Shanghai Sangon Biological Engineering
Technology & Service Co. Ltd (China). Ampliﬁcation of
b-actin was used for the determination of the internal
mRNA expression levels. Brieﬂy, PCR was performed at
951C with initial denaturation for 5min, followed by 30
cycles of ampliﬁcation at 941C( 1 m i n ) ,5 9 1C (1min)
and 721C (1min). Finally, the samples were extended at
721C for 10min. The speciﬁcity of ampliﬁcation was
checked by assessing whether a fragment of the expected
size had been obtained with the positive control. Aliquots
of the synthesized PCR products were separated by
electrophoresis on a 1.5% agarose gel and analysed by
GEL-PRO 3.1 software.
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The cells (being transfected with plasmids and/or
stimulated by PDGF-BB) and the frozen liver tissues
collected in the animal experiments were homogenized
in lysis buffer. Phosphatase inhibitor (Sigma) was added
before use to prevent protein dephosphorylation. Protein
lysates were sonicated and centrifuged at 10000r.p.m.
(13428 g)a t4 1Cf o r1 0 m i n .W e s t e r nb l o tw a sp e r -
formed as described elsewhere (11). The primary anti-
bodies used for Western blot were PDGFR-b polyclonal
antibody (Santa Cruz; Santa Cruz, CA, USA), a-SMA
polyclonal antibody (Abcam, Cambridge, UK), b-actin
polyclonal antibody (Chemicon, Billerica, MA, USA),
extracellular-signal-relatedkinase (ERK)andpERKpoly-
clonal antibody (Santa Cruz). The bands were visua-
lized using the ECL Plus reagents (Sigma) according to
the manufacturer’s instructions. Protein signals were
normalized to b-actin levels.
Proliferation assay
After plasmid transfection and/or PDGF-BB stimulation,
cells were stimulated with 10ı `M 5-bromodeoxyuridine
(BrdU; Upstate, Billerica) for 1h. For immunoﬂuores-
cence analysis, cells were ﬁxed with 4% paraformalde-
hyde solution and then incubated with HCl and borate
buffer. BrdU in the nucleus was detected by immunocy-
tochemical staining using a mouse monoclonal ﬂuores-
cein isothiocyanate (FITC)-labelled antibody to BrdU
(Abcam). Light nuclear counterstaining was performed
with 4,6-diamidino-2-phenylindole (Roche, Nutley, NJ,
USA)beforemounting.CellswereanalysedusingaLeica
TCS SP2 confocal microscope system (Leica, Solms,
Germany). HSCs proliferation was measured by green
staining of nuclei that had incorporated BrdU. Results
were expressed as meanSD of cells that had incor-
porated BrdU (percentage of BrdU-positive cells). The
ﬂow cytometry analysis of BrdU incorporation was
performed according to the protocol of BD Bios-
ciences (http://www.bdbiosciences.com/pharmingen/
protocols/BrdU_Incorporation.shtml) and analysed
using a FACS Aria Flow Cytometer System (BD
Biosciences, San Jose, CA, USA).
Localization of LacZ gene expression in bile duct
ligation and dimethylnitrosamine models
All the animals [Sprague–Dawley (SD) rats] weighing
about 200g were housed in cages with stainless-steel
wire tops and with 12-h light–dark cycles under stan-
dard animal laboratory conditions in the speciﬁc
pathogen-free-grade animal room of the Experimental
Animal Center of the Second Military Medical Univer-
sity. The rats had free access to standard rat chow and
water. This study was approved by the Local Ethical
Committee of the Second Military Medical University.
To induce the DMN model, 10 male SD rats received
DMN (Tianjin Chemical Reagent Research Institute,
Tianjin, China) dissolved in saline at a dose of 10ml
DMN/kg by a peritoneal injection for three consecu-
tive days each week for 3 weeks. On the 21st day, three
survivors were treated with pCMV–NC–LacZ by the
hydrodynamics-based transfection method. Brieﬂy, a
total of 15ml Ringer’s solution containing 100mg
pCMV–NC–LacZ/200g body weight was injected in
17s via the tail vein. Another three surviving DMN-
treated rats without plasmid transfection were used as
control. For the BDL model, 10 male SD rats were
anaesthetized with chloral hydrate, and the common
bile duct was double ligated with 4-0 silk ligatures and
transected. On the 14th day, pCMV–NC–LacZ treat-
ment with the hydrodynamics-based transfection
method was performed in three survivors as described
above and another three surviving BDL rats were used
as untransfected control.
Twenty-four hours after pCMV–NC–LacZ treat-
ment, all the BDL- and DMN-treated rats were anaes-
thetized and perfused, the livers were taken out and
post-ﬁxed with 4% paraformaldehyde and 0.2% picric
acid in phosphate buffer and cut into 8-mm-thick
sections. The sections were incubated with rabbit
anti-a-SMA polyclonal antibody (Bios, Beijing, Chi-
na) and mouse anti-b-gal monoclonal antibody (Pro-
mega, Madison, WI, USA) for 24h at 41C, then
washed in phosphate-buffered saline (PBS) and incu-
bated with FITC-labelled anti-rabbit immunoglobulin
G (IgG) antiserum and Cy5-labelled anti-mouse IgG
antiserum (Jackson, West Grove, PA, USA) for 30min
at 371C. The sections were again washed in PBS and
then transferred to slides and coverslipped. a-SMA
and b-gal immunoﬂuorescence were visualized in the
same sections using a Leica TCS SP2 confocal micro-
scope system (Leica).
Animal experiments of gene therapy
In the DMN model, 48 male SD rats weighing about
200g were randomly divided into the normal group
(n=12) and the DMN-treatment group (n=36). All
the animals in the DMN-treatment group received
DMN treatment as described above, and were ran-
domly assigned to the following three groups (12 in
each): pCMV–shRNA–LacZ treatment group, Ringer’s
solution group and pCMV–NC–LacZ treatment as the
negative control group.
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200g were randomly assigned to the normal group
(n=11), the sham-operated group (n=11) and the
BDL group(n=33). In the BDL group, hepatic ﬁbrosis
was induced as described above. In sham-operated
rats, blunt dissection, but without ligation and trans-
ection of the common bile duct, was performed. The
33 BDL rats were divided into three groups as for the
DMN model.
All the solutions were injected by a hydrodynamics-
based transfection method. Brieﬂy, a total of 15ml
solution containing 100mg plasmids/200g body weight
was injected in 17s via the tail vein at 24h before DMN
treatment or BDL operation, and then 10ml containing
100mg plasmids/200g body weight in 17s via the tail
vein every 5 days for 3 weeks in the DMN model or 2
weeks in the BDL model. At the end of 2 or 3 weeks, the
rats were sacriﬁcedand serum samples were collectedfor
biochemical tests. The right lobe of the livers was taken
from the abdominal cavity, then soaked with 10%
neutral formaldehyde for histology and preserved at
701C for Western blot analysis.
Evaluation of hepatic ﬁbrosis
The pathogenesis of hepatic ﬁbrosis induced by DMN or
BDL and the effects of PDGFR-b shRNA were evaluated
through Masson’s trichrome staining. The stained
sections were examined under an Olympus research
microscope, BX61 (Olympus, Tokyo, Japan). The stage
of ﬁbrosis was graded as stages 0 (no ﬁbrosis) to 4
(cirrhosis), as shown in Table 1. The densitometry of the
collagen was quantiﬁed using IMAGE-PRO PLUS software.
Immunohistochemistry for a-smooth muscle actin
and platelet-derived growth factor b subunit on liver
sections
The parafﬁn sections were deparafﬁnized using xylene
and alcohol and hydrated with water, and then treated
with PDGFR-b polyclonal antibody or a-SMA mono-
clonal antibody (Boster, Wuhan, China) as primary
antibodies, followed by biotinylated secondary anti-
body and streptavidin peroxidase. The sections were
counterstained with Mayer’s haematoxylin, treated
with ammonia water and mounted using an aqueous-
based mounting medium and photographed. The
staining intensity of a-SMA and PDGFR-b was quan-
tiﬁed using IMAGE-PRO PLUS software.
Statistics
Results were presented as means of three independent
experiments (SD). In the semiquantitative analysis
of histological staging, nonparametric tests (Wilcox-
on’s test) were used; other statistical analyses were
performed using an unpaired Student’s t test. Differ-
ences were considered to be signiﬁcant or highly
signiﬁcant at Po0.05 or Po0.01 respectively.
Results
Platelet-derived growth factor b subunit short
hairpin RNA downregulated platelet-derived growth
factor b subunit expression and suppressed hepatic
stellate cells activation in vitro
Reverse transcription-polymerase chain reaction re-
sultsshowed that PDGFR-b shRNAdownregulatedthe
PDGFR-b mRNA expression by 403.14, 554.67,
724.20 and 556.19% at 24, 48, 72 and 96h
respectively (Fig. 1A). In addition, PDGFR-b protein
expression was downregulated by 334.51, 475.72,
607.59 and 827.13% at 24, 48, 72 and 96h
respectively, indicating that the highest gene-silencing
efﬁcacy of PDGFR-b shRNA appeared in 72h, while
the protein level was reduced more signiﬁcantly in 96
than 72h, which may be because of the time period of
transcription and translation from mRNA to protein
(Fig.1B).AstheactivationofHSCscharacterizedby the
expression of a-SMA is the key event of the pathogen-
esis of hepatic ﬁbrosis, the effects of PDGFR-b shRNA
on the mRNA and protein expression of a-SMA were
investigated in HSCs. The results revealed that the a-
SMA expression in HSCs had increased signiﬁcantly
after PDGF-BB stimulation, which was impeded by
PDGFR-b shRNA transfection (Fig. 1C).
Platelet-derived growth factor b subunit short
hairpin RNA blocked the mitogen-activated protein
kinase signalling transduction pathway and inhibited
hepatic stellate cells proliferation in vitro
To investigate the effect of PDGFR-b shRNA on HSCs
proliferation, BrdU incorporation was used and
Table1. Stages of ﬁbrosis
Description Score Deﬁnition
No ﬁbrosis 0 Normal connective tissue
Portal ﬁbrosis 1 Fibrous portal expansion
Periportal
ﬁbrosis
2 Periportal ﬁbrosis with short septa
extending into lobules or rare porto-
portal septa (intact architecture)
Septal ﬁbrosis 3 Fibrous septa reaching adjacent portal
tracts and terminal hepatic venule
(architecture distortion, but no
obvious cirrhosis)
Cirrhosis 4 Diffuse nodular formation
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The results showed that the HSCs proliferation pro-
moted by PDGF-BB stimulation was signiﬁcantly
suppressed by PDGFR-b shRNA (Fig. 2A). Further-
more, Western blot analysis revealed that the phos-
phorylation of ERK had increased signiﬁcantly after
stimulation by PDGF-BB, which was impeded by
PDGFR-b shRNA or PD98059 (Fig. 2B). As a positive
control, PD98059 is a speciﬁc inhibitor of ERK phos-
phorylation.
Platelet-derived growth factor b subunit short
hairpin RNA could be delivered into activated
hepatic stellate cells in rats
Because PDGFR-b shRNA was conﬁrmed to suppress
HSCs activation and inhibit HSCs proliferation
in vitro, what concerned us was whether it could be
delivered into activated HSCs by a hydrodynamics-
based transfection method in vivo. The double-label
immunoﬂuorescence showed that pCMV–shRNA–-
LacZ could be delivered into liver cells, including
hepatocytes and a-SMA-positive activated HSCs in
DMN rats and BDL rats, successfully by the hydro-
dynamics-based transfection method (Fig. 3).
Platelet-derived growth factor b subunit short
hairpin RNA relieved the liver injury in rats
Because PDGF and PDGFR-b play important roles in
the pathogenesis of hepatic ﬁbrosis, we investigated
the effectof PDGFR-bshRNAonliverinjury in rats. In
the DMN animal model, the results revealed that
serum total bilirubin (TB), alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) levels
were signiﬁcantly increased in DMN control rats
compared with the normal rats, and signiﬁcantly
con
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α-SMA
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+
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C
Fig. 1. Effect of platelet-derived growth factor b subunit
(PDGFR-b) short hairpin RNA (shRNA) on PDGFR-b and a-smooth
muscle actin (a-SMA) expression in hepatic stellate cells (HSCs).
(A)and (B) show the PDGFR-b mRNA and protein expressionafter
transfection with PDGFR-b shRNA for 24, 48, 72 and 96h. ‘con’
representsHSCswithouttreatment.(C) Showsa-SMAmRNAand
protein expression in HSCs without treatment, HSCs with
platelet-derived growth factor (PDGF)-BB, HSCs with pCMV–NC–
LacZandPDGF-BBandHSCswithpCMV–shRNA–LacZandPDGF-
BB. The results demonstrated that the a-SMA expression of HSCs
was signiﬁcantly increased (P=0.002) after PDGF-BB stimulation,
which was impeded by PDGFR-b shRNA transfection (P=0.001).
pCMV–shRNA, plasmid pCMV–shRNA—LacZ; pCMV–NC,
negative control of plasmid pCMV–NC–LacZ.
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Fig. 2. Effect of platelet-derived growth factor b subunit
(PDGFR-b) short hairpin RNA (shRNA) on the proliferation of
hepatic stellate cells (HSCs). (A) showed statistical results of
bromodeoxyuridine incorporation detected by immuno-
ﬂuorescence (IF) and ﬂow cytometry (FACs) in HSCs without
treatment (HSC), HSCs with platelet-derived growth factor
(PDGF)-BB (HSC1PDGF), HSCs with pCMV–NC–LacZ and PDGF-
BB (HSC1PDGF1RNAcon) and HSCs with pCMV–shRNA–LacZ
and PDGF-BB (HSC1PDGF1RNA interference). The results
revealed that PDGF-BB signiﬁcantly promoted the proliferation
of HSCs (P=0.008 with ﬂow cytometry analysis and P=0.012
with immunoﬂuorescence), which was inhibited by pCMV–
shRNA–LacZ (P=0.003 with ﬂow cytometry analysis and
P=0.006 with immunoﬂuorescence). Po0.05, Po0.01.
(B) shows the representative graph of extracellular-signal-related
kinase (ERK) phosphorylation in HSCs without treatment, HSCs
with PDGF-BB, HSCs with pCMV–NC–LacZ and PDGF-BB, HSCs
with pCMV–shRNA–LacZ and PDGF-BB and HSCs with PD98059
and PDGF-BB by Western blot analysis. PD98059 is a speciﬁc
inhibitor of ERK phosphorylation.
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compared with the pCMV–NC–LacZ treatment rats
(Fig. 4A and B). In the BDL animal model, the results
demonstrated that serum TB, direct bilirubin, ALT
and AST levels were signiﬁcantly increased in the BDL
control group compared with the sham-operated
group, which was eliminated by pCMV–shRNA–LacZ
treatment (Fig. 4C and D).
Platelet-derived growth factor b subunit short
hairpin RNA downregulated platelet-derived growth
factor b subunit expression and inhibited hepatic
stellate cells activation in rats
In the previous study, we have demonstrated that
PDGFR-b shRNA could decrease the mRNA and
protein expression of PDGFR-b and a-SMA in vitro.
To further conﬁrm its effect on the expression of
PDGFR-b and a-SMA in vivo, a PDGFR-b shRNA
expression plasmid was constructed and delivered into
a rat model of hepatic ﬁbrosis induced by DMN and
BDL. In this study, Western blot analysis indicated that
both PDGFR-b and a-SMA protein levels were sig-
niﬁcantly increased in DMN treatment rats and BDL
rats, and remarkably reduced by pCMV–shRNA–LacZ
treatment. The results were conﬁrmed by immunohis-
tochemical examination, implying that PDGFR-b
shRNA could downregulate PDGFR-b expression and
inhibit HSCs activation in vivo as well (Figs 5B, C
and 6B, C).
Platelet-derived growth factor b subunit short
hairpin RNA ameliorated hepatic ﬁbrosis in rats
Masson’s trichrome staining of liver sections showed
periportal ﬁbrosis with ﬁbrous septa extending to
adjacent portal tracts and the terminal hepatic venule
in BDL rats and DMN treatment rats. Severe choles-
tasis and bile duct hyperplasia were observed in BDL
rats, and massive vacuolardegeneration of hepatocytes
Fig. 3. Localization of LacZ gene expression in the hepatic
ﬁbrosis rat model. The immunoﬂuorescence graph of b-gal
staining (green) in a dimethylnitrosamine (DMN)-treated rat and
a bile duct ligation (BDL) rat (A) showed that the transgenes
were widely distributed in hepatic lobules, mainly periportal and
pericentral areas, with a magniﬁcation of 40. The double-
label immunoﬂuorescence graph of b-gal (green) and a-smooth
muscle actin (a-SMA) (red) showed that in the liver section of
DMN-treated rats (B) and BDL rats (C), the transgenes could be
expressed in a-SMA-positive HSCs, magniﬁcation of 63. The
‘untransfected control’rats, which indicate DMN-treated rats (B)
or BDL rats (C) without pCMV–short hairpin RNA (shRNA)–LacZ
transfection, were used to exclude unspeciﬁc staining of b-gal.
The white arrows point to the cells with a-SMA and b-gal,
double positive, the red arrows point to the hepatocytes
residing in the liver cell cord and the pink arrows point to
the a-SMA-positive HSCs that were not transfected with
pCMV–shRNA–LacZ. The results illustrated that pCMV–
shRNA–LacZ could be delivered into activated HSCs by a
hydrodynamics-based transfection method.
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Chen et al. PDGFR-b siRNA ameliorates hepatic ﬁbrosisand intense neutrophilic inﬁltration were observed in
DMN treatment rats, suggesting that the hepatic
ﬁbrosis animal model was established successfully.
Hepatic ﬁbrosis and cholestasis were signiﬁcantly
relieved by pCMV–shRNA–LacZ treatment in the
DMN model or the BDL model compared with the
pCMV–NC–LacZ treatment group, which was char-
acterized as short septa extending into lobules or
portal–portal septa (Figs 5A and 6A; Tables 2 and 3).
The densitometry measurement showed that the per-
centage of collagen area was increased more than
80- or 60-fold in the DMN rats or the BDL rats
compared with the normal rats (Po0.001 or
Po0.001), while in pCMV–shRNA–LacZ treat-
ment rats, it was cut down by about 45 or 60%
compared with pCMV–NC–LacZ treatment rats in
250
200
150
100
50
0
1050
ALT
AST
900
750
600
450
300
150
0
**
** **
**
Normal
Sham
Model
pCMV-NC
pCMV-shRNA
S
e
r
u
m
 
t
r
a
n
s
a
m
i
n
a
s
e
 
(
U
/
L
)
ALT AST
Normal
Model
pCMV-shRNA
pCMV-NC
**
* **
**
S
e
r
u
m
 
t
r
a
n
s
a
m
i
n
a
s
e
 
(
U
/
L
)
300
14
B
**
** *
* **
*
12
10
8
6
4
2
0
350
D
TB
DB
300
250
200
150
100
50
0
Normal
Sham
Model
pCMV-NC
pCMV-shRNA
S
e
r
u
m
 
b
i
l
i
r
u
b
i
n
 
(
µ
m
o
l
/
L
)
Normal
Model
pCMV-NC
pCMV-shRNA
S
e
r
u
m
 
b
i
l
i
r
u
b
i
n
 
(
µ
m
o
l
/
L
)
A
C
Fig. 4. Effect of platelet-derived growth factor b subunit (PDGFR-b) short hairpin RNA (shRNA) on serum biochemical parameters of
experimental hepatic ﬁbrosis induced by dimethylnitrosamine (DMN) or bile duct ligation (BDL) treatment. (A) and (B) show the effect
of PDGFR-b shRNA on the serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TB) levels of
experimental hepatic ﬁbrosis induced by DMN. The results demonstrated that serum TB, ALTand AST levels were signiﬁcantly
increased in the DMN model group compared with the normal group (TB: P=0.001; ALT: Po0.001; AST: P=0.044), which was
impeded by pCMV–shRNA–LacZ treatment (TB: P=0.036; ALT: P=0.008; AST: Po0.001 compared with the pCMV–NC–LacZ
treatment group); (C) and (D) show the effect of PDGFR-b shRNA on the serum TB, direct bilirubin (DB), ALTand AST levels of
experimental hepatic ﬁbrosisinduced by BDL. The results revealed that serum TB, DB, ALTand AST levels wereincreasedsigniﬁcantly in
the BDL model group compared with the sham-operated group (TB: Po0.001; DB: Po0.001; ALT: P=0.002; AST: P=0.001), which
was inhibited by pCMV–shRNA–LacZ treatment (TB: P=0.048; DB: P=0.044; ALT: P=0.008; AST: Po0.001 compared with the
pCMV–NC–LacZ treatment group). Po0.05, Po0.01.
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0.006). These results clearly indicated that PDGFR-b
shRNA could ameliorate the hepatic ﬁbrosis induced
by BDL and DMN.
Discussion
Hepatic ﬁbrosis and its end-stage sequelae cirrhosis
represent a major worldwide health problem. Consider-
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Fig. 5. Effect of platelet-derived growth factor b subunit (PDGFR-b) short hairpin RNA (shRNA) on the histopathology and immuno-
histochemistry of experimental hepatic ﬁbrosis induced by dimethylnitrosamine (DMN) treatment. (A) shows a representative graph of
Masson’s trichrome staining (the ﬁrst line, magniﬁcation of 20), PDGFR-b immunohistochemical staining (the second line,
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Chen et al. PDGFR-b siRNA ameliorates hepatic ﬁbrosisable evidence suggests that HSCs activation is central
to the ﬁbrotic process. During hepatic ﬁbrosis, HSCs
undergo a process of activation, which coincides with
increased cell proliferation and excessive production
of ECM. An early proliferative response in HSCs
is mainly mediated by PDGF and coupled with sequ-
ential expression of PDGFR-b. PDGF binding to
PDGFR-b induces PDGFR autophosphorylation of
tyrosine residues, initiating a mitogen-activated pro-
tein kinase (MAPK) signalling transduction pathway
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vated HSCs induced by PDGF (12). Because PDGF
and PDGFR-b have been implicated in hepatic ﬁbro-
sis, many antiﬁbrosis strategies focus on reducing the
secretion of PDGF, inhibiting the coupling of PDGF
and PDGFR, blocking the MAPK signal transduction
pathway to reduce PDGF-induced HSCs proliferation
subsequently. The antisense mRNA of the PDGF-B
chain, tyrosine kinase inhibitor genistein and STI-571,
selective Na
1/H
1 exchange inhibitor cariporide,
dominant-negative soluble PDGFR-b and selective
PDGFR tyrosine kinase inhibitor AG1295 have been
conﬁrmed to reduce HSCs proliferation and attenuate
hepatic ﬁbrosis (13–19). We have previously devel-
oped an anti-PDGFR-b ribozyme to block the signal
transduction pathway of PDGF, inhibit HSCs prolif-
eration and activation and decrease the production of
ECM subsequently in vitro (20). Here, we demon-
strated that downregulation of PDGFR-b by RNA
interference (RNAi) could also result in the inhibition
of ERK phosphorylation; thus, the blockage of the
MAPK signal transduction pathway and the suppres-
sion of HSCs proliferation in vitro, the liver injury and
hepatic ﬁbrosis induced by DMN and BDL could also
be relieved by PDGFR-b shRNA treatment. In addi-
tion, we conﬁrmed the reduced a-SMA expression by
PDGFR-b shRNA treatment not only in vitro but also
in vivo, suggesting that the activation of HSCs was
suppressed by PDGFR-b shRNA. This ﬁts well with
other studies demonstrating that inhibitors of PDGF
decreased a-SMA immunoreactivity (21).
RNA interference is the process of sequence-
speciﬁc, post-transcriptional gene silencing, initiated by
double-stranded RNA. This is a multistep process that
involves generation of 19–21 nucleotide siRNA, result-
ing in degradation of the homologous RNA (22).
Delivery of chemically synthesized siRNAs can result in
sequence-speciﬁc translation arrest in vitro. However,
the disadvantages of chemically synthesized siRNA, such
as a higher cost, increased synthesis time, easy degrada-
tion by serum nucleases and transient downregulation
of gene expression, restrict its application in vivo (23).
To overcome these problems, vector-based systems
expressing shRNA that are cleaved by the endogenous
nuclease Dicer to produce siRNA have been developed
(24). The shRNA was structurally made by stem–loop
type of siRNA. In this study, we constructed a PDGFR-b
shRNA expression plasmid, in which PDGFR-b shRNA
embedded in an miR30-based context was driven by a
CMV promoter. Our results clearly demonstrated the
antiﬁbrogenic effect of PDGFR-b shRNA expression
plasmid on an experimental hepatic ﬁbrosis animal
model induced by BDL and DMN.
A numberof different methods havebeen developed
to deliver siRNA in vivo. Among the methods at-
tempted in rodents, rapid infusion by hydrodynamic
injection of siRNA via the tail vein has been recom-
mended as one of the best techniques to deliver siRNA
into the liver (25–27). Several groups have used this
technique to introduce siRNA- or shRNA-expressing
constructs successfully into mice, achieving efﬁcient
delivery and subsequent silencing of target genes in the
liver (28, 29). In this study, we also used this method
to deliver the plasmid-expressing PDGFR-b shRNA
into the target organ: the liver. What concerned us is
whether hydrodynamic injection can deliver siRNA
into HSCs, especially activated HSCs. We detected the
LacZ reporter gene expression in BDL rats and DMN
rats by double-label immunoﬂuorescence, and the
results demonstrated that the LacZ gene can be
expressed in not only hepatocytes but also a-SMA-
positive HSCs. Because PDGFR-b is only expressed in
HSCs in the liver, we deduce that PDGFR-b shRNA
driven by the CMV promoter can only exert its effect
in HSCs, although it can be delivered into different cell
types including hepatocytes. As the highest gene-
silencing efﬁcacy of PDGFR-b shRNA appeared in
72h in vitro, we delivered the plasmid into rats by a
hydrodynamics-based transfection method every 5
Table2. Effect of PDGF receptor b subunit short hairpin RNA on
hepatic ﬁbrosis of dimethylnitrosamine rats
Group/Stage 1–2 0–1 2–3 3–4 U
Normal 12 0 0 0 –
Model 0 0 10 0 4.3875
pCMV-NC 0 0 9 0 –
pCMV-shRNA 0 7 2 0 3.9622
##
To score the stage of ﬁbrosis, three ﬁelds of microscope in the liver
section of each rat were scored, and the average score was the stage of
ﬁbrosis.
Po0.01 compared with the normal group.
##Po0.01 compared with the pCMV-NC-LacZ treatment.
Table3. Effect of PDGF receptor b subunit short hairpin RNA on
hepatic ﬁbrosis of bile duct ligation rats
Group/Stage 1–2 0–1 2–3 3–4 U
Normal 11 0 0 0 –
Sham 11 0 0 0 –
Model 0 0 8 1 4.0390
pCMV-NC 0 0 6 2 –
pCMV-shRNA 0 8 0 0 3.4668
##
To score the stage of ﬁbrosis, three ﬁelds of microscope in the liver
section of each rat were scored, and the average score was the stage of
ﬁbrosis.
Po0.01 compared with the normal group.
##Po0.01 compared with the pCMV-NC-LacZ treatment group.
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in vivo. Considering the poor conditions of rats after
BDL operation and DMN treatment, we decreased the
injection volume to 10ml/200g body weight from the
second injection.
The lessened liver injury by PDGFR-b shRNA treat-
ment was documented by our study, which was
characterized by the lower serum levels of aminotrans-
ferase and bilirubin in PDGFR-b shRNA treatment
rats than in the control rats. The results are interesting
because the increased serum aminotransferase reﬂects
the damage of hepatocytes, while the target cell of
PDGFR-b shRNA is HSCs. Friedman (30) believed
that ﬁbrosis in the Disse space may block the exchange
of molecules between the sinusoidal space and the
hepatocytes, thereby impairing the functioning of
hepatocytes. Thus, a reduction of ﬁbrosis in this space
might improve liver function more than might other-
wise be expected. Moreover, another study eliminated
transforming growth factor-b (TGF-b) signalling by
adenovirus-mediated expression of a dominant-nega-
tive type-II TGF-b receptor in a DMN-induced hepa-
tic ﬁbrosis rat model, and the results revealed that it
could reduce ALT levels of the model control more
than 60-fold, and the rats in the model control all died
of liverdysfunction (31).Therefore, the improved liver
function by PDGFR-b shRNA may be attributed to the
decreased ECM deposition.
In conclusion, the data presented here provide evi-
dence that PDGFR-b shRNA is active as an antiﬁbro-
genic gene therapeutic method able to reduce the
expression of PDGFR-b protein and inhibit the activa-
tion of HSCs in ﬁbrotic liver. The beneﬁcial effects of
RNAi technique make it a promising therapeutic meth-
od for the treatment of hepatic ﬁbrosis in the future.
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